Tympanic videos classified into AOM versus no AOM had sensitivity of 93.8%, specificity of 93.5%.
Otic Disorders
— DRUG MONOGRAPHS BY SUBSECTION —
News and Features
No benefits seen for high-dose glucocorticoids for idiopathic sudden sensorineural hearing loss, but there was an increase in adverse events
The US Food and Drug Administration (FDA) approved a wide range of therapies in 2023, including many new molecular entities and biological products. The information below is organized by the month in which the product received approval.
Findings seen in analyses adjusted for demographics, hearing levels, and medical history among adults with hearing loss.
Most prevalent exposure among children is personal listening devices; duration should be considered as well as volume.
All children should have risk assessment for hearing changes; prompt objective screening recommended in case of clinical or caregiver concern.
Benefits seen for hearing difficulty, issues with background noise, and use of hearing aids.
Though in key measures of understandability and actionability, materials performed worse than institution-generated materials.
Self-reported and clinical outcomes similar to those seen with audiologist-fitted hearing aids.
Risk for all-cause dementia increased for those with hearing loss without hearing aids, but not for those with hearing aid use.
The approval was based on data from the phase 3 BUTTERFLEYE and FIREFLEYE trials.
Socially disadvantaged children less likely to receive treatment for recurrent or suppurative otitis media
Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children.
The approval was based on data from 2 pivotal phase 3 trials, which evaluated Pedmark in pediatric patients undergoing treatment with cisplatin-based chemotherapy.
The final rule takes effect in 60 days and consumers will be able to purchase hearing aids directly from stores or online retailers as soon as mid-October.
No increased risk for tinnitus seen with low-dose aspirin, but increase seen with moderate-dose aspirin for those younger than 60 years, NSAIDS, acetaminophen
The application could not be approved in its present form due to manufacturing deficiencies.
Proposal would create a category of hearing aids that could be sold directly to consumers, without medical exam or audiologist fitting
Study findings did show high adherence to guidelines with respect to medication use.
Cumulative incidence highest in patients aged 5 years and younger; factors that influence development include cumulative dose of cisplatin
- Loading...
